Compare Abeona Therapeutics Inc (ABEO) vs iShares Core MSCI EAFE ETF (IEFA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares Core MSCI EAFE ETF — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while iShares Core MSCI EAFE ETF trades at $96.31. Which is the better fit depends on your goals.
| ABEO | IEFA | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $7.23 | $98.56 |
52-Week Low | $4.17 | $81.70 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
IEFA trades at $98.31, up 1.04% with a bullish technical signal from moving averages. The ETF focuses on developed international markets excluding North America, offering diversification from US concentration risks. Recent news highlights strong performance comparisons against peers like VXUS and EEM, with a competitive 3.30% dividend yield and low 0.07% expense ratio. Central bank policy shifts in Europe and Japan present both opportunities and headwinds for international exposure.
The outlook remains positive given technical momentum and diversification benefits, though currency fluctuations and developed market monetary policy changes pose risks. Analyst sentiment leans bullish with the ETF positioned as a core holding for international diversification, but investors should monitor geopolitical developments and relative performance against US equities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →
